title: Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.
authors: Department of Oncology, St Vincent's University Hospital, Dublin, Ireland. Electronic address: g.gullo@svuh.ie.
authors: G
authors: G
authors: Gullo
authors: Oncology and Haematology Unit, Humanitas Cancer Center, Rozzano, Italy.
authors: M
authors: M
authors: Zuradelli
authors: Department of Oncology, St Vincent's University Hospital, Dublin, Ireland.
authors: F
authors: F
authors: Sclafani
authors: Oncology and Haematology Unit, Humanitas Cancer Center, Rozzano, Italy.
authors: A
authors: A
authors: Santoro
authors: Department of Oncology, St Vincent's University Hospital, Dublin, Ireland.
authors: J
authors: J
authors: Crown
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D000077143:Docetaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab